These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 12455410)
41. Plant substances as anti-HIV agents selected according to their putative mechanism of action. Cos P; Maes L; Vanden Berghe D; Hermans N; Pieters L; Vlietinck A J Nat Prod; 2004 Feb; 67(2):284-93. PubMed ID: 14987070 [TBL] [Abstract][Full Text] [Related]
42. Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore. Hong H; Neamati N; Winslow HE; Christensen JL; Orr A; Pommier Y; Milne GW Antivir Chem Chemother; 1998 Nov; 9(6):461-72. PubMed ID: 9865384 [TBL] [Abstract][Full Text] [Related]
43. Wikstroelide M potently inhibits HIV replication by targeting reverse transcriptase and integrase nuclear translocation. Zhang X; Huang SZ; Gu WG; Yang LM; Chen H; Zheng CB; Zhao YX; Wan DC; Zheng YT Chin J Nat Med; 2014 Mar; 12(3):186-93. PubMed ID: 24702804 [TBL] [Abstract][Full Text] [Related]
44. A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Savarino A Expert Opin Investig Drugs; 2006 Dec; 15(12):1507-22. PubMed ID: 17107277 [TBL] [Abstract][Full Text] [Related]
45. Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection. Terrazas-Aranda K; Van Herrewege Y; Hazuda D; Lewi P; Costi R; Di Santo R; Cara A; Vanham G Antimicrob Agents Chemother; 2008 Jul; 52(7):2544-54. PubMed ID: 18474579 [TBL] [Abstract][Full Text] [Related]
47. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system. Jármy G; Heinkelein M; Weissbrich B; Jassoy C; Rethwilm A J Med Virol; 2001 Jul; 64(3):223-31. PubMed ID: 11424108 [TBL] [Abstract][Full Text] [Related]
48. Evolution of HIV-1 reverse transcriptase and integrase dual inhibitors: Recent advances and developments. Gill MSA; Hassan SS; Ahemad N Eur J Med Chem; 2019 Oct; 179():423-448. PubMed ID: 31265935 [TBL] [Abstract][Full Text] [Related]
49. L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350). Robinson WE Antiviral Res; 1998 Aug; 39(2):101-11. PubMed ID: 9806487 [TBL] [Abstract][Full Text] [Related]
50. Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication. King PJ; Ma G; Miao W; Jia Q; McDougall BR; Reinecke MG; Cornell C; Kuan J; Kim TR; Robinson WE J Med Chem; 1999 Feb; 42(3):497-509. PubMed ID: 9986720 [TBL] [Abstract][Full Text] [Related]
51. HIV-1 integrase inhibitors: 2005-2006 update. Dayam R; Gundla R; Al-Mawsawi LQ; Neamati N Med Res Rev; 2008 Jan; 28(1):118-54. PubMed ID: 17979144 [TBL] [Abstract][Full Text] [Related]
52. Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions. Svarovskaia ES; Barr R; Zhang X; Pais GC; Marchand C; Pommier Y; Burke TR; Pathak VK J Virol; 2004 Apr; 78(7):3210-22. PubMed ID: 15016842 [TBL] [Abstract][Full Text] [Related]
53. [How proviral DNA is integrated into the host cell DNA and how this process can be inhibited]. Mirambeau G Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():11-6. PubMed ID: 19572420 [TBL] [Abstract][Full Text] [Related]
54. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
55. HIV-1 integrase: the next target for AIDS therapy? d'Angelo J; Mouscadet JF; Desmaële D; Zouhiri F; Leh H Pathol Biol (Paris); 2001 Apr; 49(3):237-46. PubMed ID: 11367559 [TBL] [Abstract][Full Text] [Related]
56. Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. McDougall B; King PJ; Wu BW; Hostomsky Z; Reinecke MG; Robinson WE Antimicrob Agents Chemother; 1998 Jan; 42(1):140-6. PubMed ID: 9449274 [TBL] [Abstract][Full Text] [Related]
57. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Buzón MJ; Massanella M; Llibre JM; Esteve A; Dahl V; Puertas MC; Gatell JM; Domingo P; Paredes R; Sharkey M; Palmer S; Stevenson M; Clotet B; Blanco J; Martinez-Picado J Nat Med; 2010 Apr; 16(4):460-5. PubMed ID: 20228817 [TBL] [Abstract][Full Text] [Related]
58. Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells. McElrath MJ; Ballweber L; Terker A; Kreger A; Sakchalathorn P; Robinson B; Fialkow M; Lentz G; Hladik F Antimicrob Agents Chemother; 2010 Feb; 54(2):763-72. PubMed ID: 19949052 [TBL] [Abstract][Full Text] [Related]
59. Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids. Zhu K; Cordeiro ML; Atienza J; Robinson WE; Chow SA J Virol; 1999 Apr; 73(4):3309-16. PubMed ID: 10074185 [TBL] [Abstract][Full Text] [Related]
60. Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase. Gu SX; Xue P; Ju XL; Zhu YY Bioorg Med Chem; 2016 Nov; 24(21):5007-5016. PubMed ID: 27658796 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]